|
|
||||||||
From the Unité de Recherche sur les Handicaps Génétiques de lEnfant, Insitut National de la Santé et de la Recherche Médicale U393, Hôpital des Enfants Malades, Paris, France.
| Abstract |
|---|
|
|
|---|
METHODS. cDNA constructs were generated that contained the retGC-1 missense mutations identified in patients related to the LCA1 locus. Mutants were expressed in COS7 cells and assayed for their ability to hydrolyze guanosine triphosphate (GTP) into cyclic guanosine monophosphate (cGMP).
RESULTS. All mutations lying in the catalytic domain showed a complete abolition of cyclase activity. In contrast, only one mutation lying in the extracellular domain also resulted in a severely reduced catalytic activity, whereas the others showed completely normal activity.
CONCLUSIONS. More than half the mutations identified in patients related to the LCA1 locus are truncating mutations expected to result in a total abolition of retGC-1 activity. Concerning missense mutations, half of them lying in the catalytic domain of the protein also result in the complete inability of the mutant cyclases to hydrolyze GTP into cGMP in vitro. In contrast, missense mutations lying in the extracellular domain, except one affecting the initiation codon, showed normal catalytic activity of retGC-1. Nevertheless, considering that all patients related to the LCA1 locus displayed the same phenotype, it can be assumed that all missense mutations would have the same dramatic consequences on protein activity in vivo as truncation mutations.
| Introduction |
|---|
|
|
|---|
Conversely, genetic heterogeneity has been accepted for a long time.5 In 1995, we localized the first disease-causing gene, LCA1, to chromosome 17p13 and confirmed the genetic heterogeneity.6 7 In 1996, we ascribed LCA1 to mutations in the photoreceptor-specific guanylyl cyclase gene (retGC-1), which catalyzes the conversion of guanosine triphosphate (GTP) into cyclic guanosine monophosphate (cGMP) in the photoreceptor cells.8 Twenty-two different mutations were identified in patients related to the LCA1 locus. Half of them were truncating mutations expected to result in the total abolition of the cyclase activity of retGC-1,9 whereas the other half were missense mutations. We report here the study of 9 of 11 of the missense mutations (M1I, W21R, L41F, N129K, R313C, R976, R995W, M1009L, and H1019P), as well as a mutation truncating the COOH end of the protein (Q1036Z), on the catalytic ability of the mutant proteins.
| Methods |
|---|
|
|
|---|
Spectrum of retGC-1 Mutations
Forty-seven retGC-1 mutations (22 different, 18
homozygous) were identified in 25 of 130 unrelated patients with LCA
(18.5%).9
Among the 22 different mutations identified, 11
were missense mutations, and 11 were truncating mutations.
Interestingly, 15 of the 25 patients were found to carry mutations
expected to result in the truncation of the retGC-1
protein9
(11 homozygotes, 3 compound heterozygotes, and 1
single heterozygote).
Expression Studies
The full length retGC-1 cDNA (3621 bp, GenBank
accession number, M92432) was cloned into the eukaryotic expression
vector PRK5 (Clonetech, Palo Alto, CA). PRK5 contains the early
promoter and the polyadenylation signal of the simian 40 virus (SV40).
Single-base substitutions (M1I, W21R, L41F, N129K, R313C, R976, R995W,
M1009L, H1019P, and Q1036Z) were created by site-directed mutagenesis
(Quickchange Site Directed Mutagenesis kit; Stratagene, La Jolla, CA),
by using oligonucleotides specific for the various mutations (not
shown, available on request). Mutant clones were transformed into
DH5
bacteria cells and sequenced before expression studies.
Monkey COS7 cells (American Type Culture Center, Rockville, MD
[ATCC]) were grown in minimum essential medium (MEM) supplemented
with 10% fetal calf serum. Before transfection, the cells
(106/80-cm2 tissue culture
flask) were grown for 24 hours in MEM with 10% fetal calf serum. For
transfection, cells were incubated in MEM chloroquine with either
normal or mutant PRK5 retGC-1 (9 µg). After 3 hours, the cells were
treated with 10% dimethyl sulfoxide (DMSO) in Hanks balanced salt
solution (2 ml) for 2 minutes. The DMSO medium was discarded, and the
cells were washed twice with MEM and incubated in fresh medium for 48
hours to allow expression of the transfected constructs. The luciferase
cDNA was cloned into a PSG5 vector and systematically cotransfected (1
µg) as a test of transfection efficiency. After 48 hours of culture,
the cells were washed twice in 5 ml ice-cold 0.02 M HEPES (pH 7.4) and
0.15 M NaCl; harvested in a centrifuge tube in a total of 1.5 ml of 20
mM HEPES (pH 7.4), 50 mM NaCl, 1 mM EDTA, and 1 mM dithiothreitol; and
broken by passage 10 times through a 22-gauge needle. The
homogenate was spun for 15 minutes at 5000g. Supernatant
protein concentration was adjusted to 4 mg/ml, and luciferase activity
was measured according to the manufacturers protocol (Luciferase
Assay System; Promega, Madison, WI). The pellet was washed in 1.5 ml of
the same buffer. Membranes were solubilized for 30 minutes on ice in
250 µl of 20 mM HEPES (pH 7.4), 100 mM NaCl, 1% Triton X-100, 10%
glycerol, and 1 mM dithiothreitol. After centrifugation for 5 minutes
at 5000g, supernatant fluid protein was adjusted to 4 mg/ml.
Two hundred micrograms of membrane protein was assayed to determine
guanylyl cyclase activities in a total reaction volume of 150 µl
containing 20 mM HEPES (pH 7.4), 0.1 mM GTP, 4 mM
MnCl2, 0.2 mM 3-isobutyl-1-methylxantine (IBMX),
and 1 µCi [
-32P]GTP. Incubations were for 20 minutes at 37°C
and were terminated by the addition of 750 µl of 120 mM zinc acetate
and 600 µl 144 mM sodium carbonate. The produced [
-32P]cGMP was
purified by neutral alumina chromatography and quantitated by liquid
scintillation counting, as described.11
| Results |
|---|
|
|
|---|
|
| Discussion |
|---|
|
|
|---|
Among the 130 unrelated LCA patients of our series, 25 were found to harbor mutations in the retGC-1 gene. For 16 (67%) of them, the predicted residual cyclase activity resulting from the combination of the activities of the mutant proteins encoded by each retGC-1 allele was dramatically reduced;T1> (Table 1) . Indeed, 11 of 16 were found to be homozygous for a truncating mutation (patients 34, 23, 3, 90, 91, 121, 110, 85, 20, 33, and 70; Table 1 ), 3 of 16 harbored a homozygous missense mutation resulting in a dramatic reduction of the cyclase activity (patients 11, 31, and 56; Table 1 ), and 2 of 16 were compound heterozygotes for a truncating mutation and a missense mutation leading to the same dramatic reduction in catalytic activity (patients 51, and 88; Table 1 ). In addition, among the nine remaining patients, three were found to carry one mutation resulting in the complete abolition of the enzyme activity (patients 72, 82, and 52; Table 1 ). One of these three patients was a single heterozygote for a mutation truncating the carboxyl terminus of the protein. The other two were found to carry one mutation residing in the extracellular (EC) domain of the protein. Finally, six of nine patients were found to carry mutations in this domain only (two single heterozygotes, patients 89 and 117; four homozygotes, patients, 60, 7, 17, and 36; Table 1 ).
|
1-antitrypsin
deficiency produce mutant molecules that, although functionally intact,
are retained in the ER and degraded.19
In fact, in a large
number of diseases, expressions of mutant proteins are targeted to the
ER and fail to reach their intended cellular location, often displaying
an ER storage phenotype with aggregated material accumulating in the
ER.20
This situation has been well documented in cystic
fibrosis, in which the most common mutation in the CFTR
gene,
F508, leads to the disease, whereas the same mutation
introduced into a recombinant CFTR channel does not abolish
the biologic activity.21 Nevertheless, this hypothesis of a misfolding of the mutant cyclase encoded by a retGC-1 gene carrying mutations in the EC domain could not be studied in our experimental conditions. Immunochemistry experiments indicate that most of the overexpressed wild-type retGC-1 protein resides in the ER (data not shown, available on request). This observation has already been described for other membrane proteins, such as the retinal specific adenosine triphosphate (ATP)-binding cassette (ABCR).22
| Acknowledgements |
|---|
| Footnotes |
|---|
Submitted for publication June 14, 2000; revised November 29, 2000; accepted January 24, 2001.
Commercial relationships policy: N.
Corresponding author: Josseline Kaplan, Unité de Recherche sur les Handicaps Génétiques de lEnfant, INSERM U393, Hôpital des Enfants Malades, 149 rue de Sèvres, 75743 Paris Cedex 15, France. kaplan{at}necker.fr
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
W. Baehr, S. Karan, T. Maeda, D.-G. Luo, S. Li, J. D. Bronson, C. B. Watt, K.-W. Yau, J. M. Frederick, and K. Palczewski The Function of Guanylate Cyclase 1 and Guanylate Cyclase 2 in Rod and Cone Photoreceptors J. Biol. Chem., March 23, 2007; 282(12): 8837 - 8847. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Zernant, M. Kulm, S. Dharmaraj, A. I. den Hollander, I. Perrault, M. N. Preising, B. Lorenz, J. Kaplan, F. P. M. Cremers, I. Maumenee, et al. Genotyping Microarray (Disease Chip) for Leber Congenital Amaurosis: Detection of Modifier Alleles Invest. Ophthalmol. Vis. Sci., September 1, 2005; 46(9): 3052 - 3059. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Coleman, Y. Zhang, G. A. J. Brown, and S. L. Semple-Rowland Cone Cell Survival and Downregulation of GCAP1 Protein in the Retinas of GC1 Knockout Mice Invest. Ophthalmol. Vis. Sci., October 1, 2004; 45(10): 3397 - 3403. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. P. M. Cremers, J. A. J. M. van den Hurk, and A. I. den Hollander Molecular genetics of Leber congenital amaurosis Hum. Mol. Genet., May 15, 2002; 11(10): 1169 - 1176. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |